← Back to Screener
Cadrenal Therapeutics, Inc. Common Stock (CVKD)
Price$4.85
Favorite Metrics
Price vs S&P 500 (26W)-69.53%
Price vs S&P 500 (4W)-39.39%
Market Capitalization$12.06M
All Metrics
Book Value / Share (Quarterly)$1.17
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-5.39
Price vs S&P 500 (YTD)-31.70%
EPS (TTM)$-6.70
10-Day Avg Trading Volume0.03M
EPS Excl Extra (TTM)$-6.70
EPS (Annual)$-6.64
ROI (Annual)-483.34%
Cash / Share (Quarterly)$1.71
ROA (Last FY)-305.95%
EBITD / Share (TTM)$-6.75
Cash Flow / Share (Annual)$-5.39
P/B Ratio4.40x
P/B Ratio (Quarterly)5.79x
Net Income / Employee (Annual)$-3
Net Interest Coverage (TTM)-0.67x
ROA (TTM)-236.95%
EPS Incl Extra (Annual)$-6.64
Current Ratio (Annual)2.72x
Quick Ratio (Quarterly)2.59x
3-Month Avg Trading Volume0.06M
52-Week Price Return-68.87%
Revenue / Employee (TTM)$0
52-Week High$17.50
EPS Excl Extra (Annual)$-6.64
26-Week Price Return-65.54%
Quick Ratio (Annual)2.59x
13-Week Price Return-43.61%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)2.72x
Enterprise Value$8.05
Revenue / Employee (Annual)$0
Cash / Share (Annual)$1.71
3-Month Return Std Dev105.00%
Net Income / Employee (TTM)$-3
ROE (Last FY)-483.34%
Net Interest Coverage (Annual)-0.67x
EPS Basic Excl Extra (Annual)$-6.64
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-6.70
ROI (TTM)-333.32%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$-0.68
Price vs S&P 500 (52W)-98.70%
Year-to-Date Return-29.06%
5-Day Price Return-3.22%
EPS Normalized (Annual)$-6.64
Month-to-Date Return-6.05%
EBITD / Share (Annual)$-6.75
LT Debt / Equity (Annual)0.00x
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-6.70
P/B Ratio (Annual)5.79x
Book Value / Share (Annual)$1.17
Price vs S&P 500 (13W)-44.30%
Beta1.30x
Revenue / Share (TTM)$0.00
ROE (TTM)-333.32%
52-Week Low$4.21
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
CVKDCadrenal Therapeutics, Inc. Common Stock | — | — | — | — | $4.85 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Cadrenal Therapeutics is developing tecarfarin, a late-stage novel oral anticoagulant designed to address unmet needs in treating rare cardiovascular conditions requiring chronic anticoagulation therapy. The reversible blood thinner is intended to prevent heart attacks, strokes, and clot-related mortality in patients with specific cardiovascular indications.